Lobbying registration dated 2026-02-23
Registrant: ANDRE ALBINATI
Client: Pharmascience Inc.
Targeted institutions:
Transport Canada (TC)
Finance Canada (FIN)
Prime Minister's Office (PMO)
House of Commons
National Defence (DND)
Innovation, Science and Economic Development Canada (ISED)
Canada Revenue Agency (CRA)
Global Affairs Canada (GAC)
Senate of Canada
Health Canada (HC)
Government funding received:
Institution: Innovation, Science and Economic Development Canada (ISED)
Amount: 7200000.00
Institution: Investissement Québec
Amount: 16650000.00
Institution: Canada Economic Development for Quebec Regions
Amount: 100000.00
Lobbying activity details:
Policies aimed at facilitating generic drugs repurposing.
Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
Seeking support from the Strategic Response Fund Program for support of biomanufacturing expansion project.
Discussion regarding the launch of new branded product in the rare disease space
Policies aimed at reinforcing pharmaceutical supply chain.
Discussion on the opioids crisis and the Health minister's expectations from pharmaceutical manufacturers
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.